BamSEC and AlphaSense Join Forces
Learn More

Tvardi Therapeutics Inc. – Material Contracts

NASDAQ: TVRD    
Share price (6/2/26): $3.17    
Market cap (6/2/26): $29.7 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.24
from 10-K 17 pages Tvardi Therapeutics, Inc. Severance and Change in Control Plan Effective Date: December 16, 2025
12/34/56
EX-10.23
from 10-K ~1 page Tvardi Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Adopted April 17, 2025
12/34/56
EX-10.1
from 10-Q 4 pages Amendment to Asset Purchase Agreement
12/34/56
EX-10.17
from 8-K 13 pages Tvardi Therapeutics, Inc. 2025 Employee Stock Purchase Plan Adopted by the Board of Directors: February 6, 2025 Approved by the Stockholders: April 1, 2025
12/34/56
EX-10.16
from 8-K 7 pages Tvardi Therapeutics, Inc. Rsu Award Grant Notice
12/34/56
EX-10.15
from 8-K 18 pages Tvardi Therapeutics, Inc. Stock Option Grant Notice
12/34/56
EX-10.14
from 8-K 29 pages Tvardi Therapeutics, Inc. 2025 Equity Incentive Plan Adopted by the Board of Directors: February 6, 2025 Approved by the Stockholders: April 1, 2025
12/34/56
EX-10.10
from 8-K 3 pages October 23, 2023 Stephen O’brien via E-Mail Dear Stephen,
12/34/56
EX-10.2
from 8-K 30 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 8 pages Indemnification Agreement
12/34/56
EX-10.41
from S-4/A 22 pages Registration Rights Agreement
12/34/56
EX-10.40
from S-4/A 26 pages Tvardi Therapeutics, Inc. Founder Restricted Stock Agreement
12/34/56
EX-10.39
from S-4/A 27 pages Tvardi Therapeutics, Inc. Founder Restricted Stock Agreement
12/34/56
EX-10.38
from S-4/A 17 pages Note Purchase Agreement
12/34/56
EX-10.33
from S-4 28 pages Exclusive License Agreement Re: Bcm Blg # [***]; Nih# [***] Entitled “Stat3 Inhibition to Treat Disorders Involving Mast Cell Degranulation”
12/34/56
EX-10.32
from S-4 30 pages Exclusive License Agreement Re: Bcm Blg # [***] Entitled “Chemical Probes That Competitively and Selectively Inhibit Stat3 Activation”, Developed by [***]
12/34/56
EX-10.31
from S-4 3 pages September 8, 2021 Yixin Chen, Phd Yjc999@gmail.com via E-Mail Dear Yixin, I Am Very Excited to Invite You to Join Tvardi Therapeutics, Inc. (The "Company") as We Continue to Develop Breakthrough Medicines for Cancer, Chronic Inflammation, and Fibrosis. in This Letter, I Would Like to Set Forth the Terms and Conditions of Your Employment Relationship With the Company
12/34/56
EX-10.30
from S-4 1 page Tvardi Therapeutics 2450 Holcombe Blvd, Suite X, Houston, Tx 77021 WWW.TVARDI.com
12/34/56
EX-10.29
from S-4 7 pages December 5, 2022 on Behalf of Tvardi Therapeutics, Inc. (The “Company”), I Am Pleased to Offer You Employment With the Company. the Purpose of This Letter Agreement (The “Agreement”) Is to Set Forth the Terms of Your Employment With the Company, Should You Accept Our Offer
12/34/56
EX-10.4
from 8-K 56 pages Asset Purchase Agreement by and Among Cara Therapeutics, Inc., Cara Royalty Sub, LLC and Vifor Fresenius Medical Care Renal Pharma, Ltd., Dated December 17, 2024
12/34/56